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Severely obese people with type 2 diabetes experience impaired emotional well-
being associated with socioeconomic disadvantage: Results from Diabetes 
MILES – Australia 
J.B. Dixon, J. L. Browne, G. Lambert, K.M. Jones, P. Reddy, F. Pouwer, & J. Speight 
Objective: To examine the emotional well-being of severely obese Australians with type 2 
diabetes, along with markers of social and economic disadvantage, using the Diabetes MILES- 
Australia dataset.  
Research Design & Methods: Diabetes MILES – Australia was a national survey of 3,338 
adults with diabetes that focused on psychosocial issues; 1795 had type 2 diabetes and reported 
BMI. We extracted data regarding depression (PHQ-9), anxiety (GAD-7), obesity- and diabetes-
related comorbidities, and demographics. The severely obese group (SOG) (BMI≥35; median 
BMI=41.6) constituted 530 (30%) of the type 2 diabetes respondents and were matched with 530 
controls (CG) (BMI<35; median BMI=28.2). Within- and between-group trends were examined.  
Results: The SOG had higher depression scores (median (IQR) 6.0 (3-12)) than CG (5.0 (2-10)); 
p<0.001, and were more likely to report moderate-severe depressive symptoms (37% versus 
27%; p<0.001). The groups did not differ on anxiety. The SOG, compared with the CG, were 
more likely to live alone (21% versus 17%), receive a disability pension (21% versus 15%), earn 
≤$40,000/year (51% versus 41%; all p<0.05), and were less likely to be employed (46% versus 
53%), tertiary educated (17% versus 26%), or have health insurance (50% versus 60%; all 
p≤0.01). Moderate-severe depression was positively associated with cumulative stressors of 
severe obesity, socioeconomic disadvantage, and obesity- and diabetes-related comorbidity. 
Conclusions: People with type 2 diabetes and severe obesity are more likely to report depressive 
symptoms and markers of social/economic disadvantage than those with diabetes alone. 
Increased awareness of these issues may assist in developing appropriate healthcare goals.  
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The determinants of the global obesity and type 2 diabetes epidemics are highly complex, arising 
from interactions between genes and a broad range of aspects of the modern post-industrial 
environment (1; 2). The issues are well beyond the simplistic lay view of “energy in, energy out 
coupled with a dose of willpower”(3). There has also been a disproportionately large rise in the 
more severe forms of obesity, that is Class II (BMI 35-40 kg/m2) and III (BMI >40 kg/m2) (4). 
Obesity, type 2 diabetes, negative affect, and cardiovascular disease are all common conditions 
that generate enormous morbidity, mortality and costs to both the individual and society. These 
conditions all appear to be inter-related in a series of causal and counter-causal pathways, in 
which the strength and the direction of relationships vary in clarity (5-11). 
Severe obesity (a chronic relapsing condition), and type 2 diabetes (a chronic progressive 
condition), require a chronic disease model of care to optimize health outcomes. In a healthcare 
setting, detailed knowledge of the patient’s physical condition, socioeconomic situation and 
emotional well-being are all required to effectively engage the patient in optimal self-care 
strategies (12).  
The associations between diabetes and obesity with impaired emotional well-being are 
established. The link between a range of mental health disorders and increasing BMI is 
influenced by age and gender, with younger women at greatest risk (13; 14). Depression is more 
common in adults with diabetes, than in the general population, and is associated with poor 
health status (11; 15; 16). Diabetes and obesity also have a major impact on employment and 
productivity. Higher medical costs and reduced productivity through disability, absenteeism and 
presenteeism are associated with obesity, especially in those with a BMI >35 kg/m2 (17). 
Association between work-related disability, depression, and socio-demographic factors in those 
with diabetes has also been described (18), but limited quality evidence is available (19). This 
emphasizes a knowledge gap and potential missed opportunities in addressing physical, 
emotional and socio-demographic factors when developing person-centered management plans.  
There is poor understanding of the compounding issues of disease, socio-demographic factors, 
and mental health and emotional well-being (19), and surprisingly little is written about morbidly 
or severely obese people with type 2 diabetes. The literature in this area is dominated by bariatric 
surgery, with articles usually describing weight loss and glycemic outcomes (20). Much of what 
is known about psychological comorbidity comes from bariatric surgical cohorts (21) and these 
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represent a highly selected subgroup, as less than 2% of those eligible (BMI >35 kg/m2) are 
treated surgically (20; 22). Successful management of type 2 diabetes and severe obesity requires 
attention to the behavioral, psychological and social aspects of these serious comorbid conditions 
(23). A systematic review of socio-demographic factors, diabetes-related 
complications/comorbidity, and the risk of incident depression included only eight eligible 
studies, of which, only three examined interactions between these factors.  In that review, 
comorbidity broadly appeared to be related to depression, but there was no interaction with 
socio-demographic factors. The authors argued for more research concerning the mediating and 
modifying factors, in order to identify groups at risk or to identify treatment strategies (19). 
Diabetes MILES - Australia (Management and Impact for Long-term Empowerment and 
Success) was a national survey of adults with type 1 and type 2 diabetes, that is focused on the 
psychosocial impact and behavioral aspects of living with the condition (23). The current case-
controlled analysis focuses on a subset of participants of Diabetes MILES – Australia and 
describes the combined emotional, socioeconomic and disease burden of severely obese 
Australians living with type 2 diabetes. Our aim was to provide insights into the overall 
condition of people with co-morbid type 2 diabetes and severe obesity, help identify those at 
greatest risk of emotional problems, and provide evidence to inform more focused, realistic and 
appropriate chronic disease management plans, with the ultimate goal of improving health and 
well-being in this group.  
Based on findings in the literature, we hypothesized that those with comorbid severe obesity and 
type 2 diabetes, compared with respondents who were not severely obese, would: 
1) report greater depression and anxiety symptoms; 
2) experience greater socio-economic hardship, greater likelihood of living alone and not 
having a partner; and that these factors would be associated with an increased risk of 
symptoms of depression and anxiety; and 
3) experience obesity- and diabetes-related physical comorbidities that would in turn be 
associated with an increase in symptoms of anxiety and depression. 
 
Research Design and Methods 
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A detailed description of the study design and methods, including a full index of validated scales 
and study-specific items and detailed sample characteristics, has been published elsewhere (23). 
A brief summary is provided here. 
Survey Design and Content 
The survey focused on the topics of emotional well-being, self-management, healthcare and 
support in relation to diabetes. In order to maximize the relevance of questions for particular 
subgroups and minimize respondent burden, multiple versions of the survey were used in the 
study.  However, all responses used in this analysis were common to all versions. 
Data Collection 
The survey was made available in hard copy and online. Survey booklets were posted to 15,000 
randomly selected National Diabetes Services Scheme (NDSS) registrants with type 1 or 2 
diabetes, aged 18-70 years. Completed postal surveys and online surveys (advertised nationally 
through diabetes-specific media) were accepted for inclusion if returned within eight weeks of 1st 
July 2011. Those who received the postal survey were invited to complete the survey online if 
they preferred. Diabetes MILES – Australia received ethical approval from the Deakin 
University Human Research Ethics Committee (reference number 2011-046).  
Participants 
In total, 3,338 eligible respondents took part in the Diabetes MILES – Australia 2011 survey, the 
majority (70%; n=2,351) completing the postal survey. All states and territories of Australia 
were represented. Respondent characteristics are reported elsewhere (23). Fifty-nine percent of 
the sample (n=1,941) had type 2 diabetes (49% women; age 59±9 years, 37% insulin-treated). 
The current paper focuses on a subset of participants with type 2 diabetes and severe obesity, 
defined as a body mass index (BMI) of ≥35g/m2. A total of 1,795 participants with type 2 
diabetes had valid data for age, gender, diabetes duration, height, and weight (for calculation of 
BMI). For this case-controlled analysis, each severely obese participant was carefully matched to 
one control participant with type 2 diabetes and BMI <35 kg/m2 on the basis of age, gender, 
duration of diabetes and use of insulin (Table 1). Each control was used once only. This 
matching allowed for confounding differences between the groups to be minimized.  
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Data extracted for this analysis: The major variables of interest in this analysis were symptoms 
of depression and anxiety, as measured by the Patient Health Questionnaire (PHQ-9) (24) and 
the Generalized Anxiety Disorder (GAD-7) questionnaire (25) respectively.  
The PHQ-9 comprises nine items, each addressing a symptom of depression and scored on a 
four-point Likert scale. The total score is computed by summing item scores (possible total score 
range 0-27, where higher scores indicate more depressive symptoms).  Scores of 5, 10, 15, and 
20 represent cut-points for mild, moderate, moderately severe and severe depression 
respectively. A binary score representing the presence/absence of moderate-severe symptoms 
(cut-off score of ≥10) was also used.  
The GAD-7 is a seven-item scale assessing symptoms of anxiety; each item is scored on a four-
point Likert scale and the total score is computed by summing item scores (possible total score 
range 0-21, where higher scores indicate more anxiety symptoms). Scores of 5, 10, and 15 
represent cut-points for mild, moderate, and severe anxiety respectively. A binary score for 
presence/absence of moderate-severe symptoms (score of ≥10) was also used (25; 26).  
The following data were also extracted from the MILES database: 
• To further characterize mental health problems: self-reported history of depression 
and/or anxiety, and any professional help received for these emotional problems. 
• To characterize socioeconomic disadvantage: marital-relationship status, housing status, 
living alone, education, household income, private health insurance (a personal choice 
influenced by the ability to pay), unemployment, and level of employment.  
• To characterize demographics and clinical characteristics of type 2 diabetes: age, 
gender, diabetes duration, insulin use, microvascular disease (renal, retinal, neuropathy), 
and macrovascular/cardiovascular disease (heart attack, stroke, or vascular disease) 
• To characterize medical comorbidity associated with obesity or type 2 diabetes; self-
reported history of fatty liver disease, hypertension, lipid disorder, polycystic ovary 
syndrome, proteinuria, sexual dysfunction, sleep apnea, and poor sleep quality. 
Statistical Methods 
The analysis involved comparing cases with controls, and an examination of increasingly severe 
obesity by stratifying the severely obese group into Class II (BMI 35-40 kg/m2), Class IIIa (BMI 
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40-45 kg/m2), and Class IIIb (BMI >45 kg/m2) to assess relative associations with increasing 
BMI.  
Cases and controls were compared using Chi-square tests for proportions, student t-tests for 
normally distributed outcomes (mean±SD) or Mann -Whitney U tests otherwise (median±IQR). 
Controls and the three levels of severe obesity were compared using one way analysis of 
variance (loge transformation if required), Kruskal-Wallis Test for non-parametric continuous 
variables, and linear association for proportions.  
Binary logistic regression analysis was used to identify factors independently associated with 
moderate to severe depressive symptoms. A logical clinically relevant hierarchical model was 
built using 5 blocks with all variables in each block included. Finally, independence confirmed 
after placing all independent associations together in one block. SPSS statistical software 18 
(SPSS Inc, Chicago,Il) was used for all analysis and two-sided p-value of ≤ 0.05 was considered 
to be statistically significant. 
 
Results 
Sample Characteristics 
The characteristics of the 1,795 participants who reported having type 2 diabetes and reported 
their height and weight (enabling BMI to be calculated) are shown in Table 1. The mean BMI for 
this cohort was 32.5 SD ±7.9 kg/m2, and the median was 31.2 (IQR 27.4 – 36.2). Increasing BMI 
was associated with being female, younger, and a considerably greater likelihood of using oral 
hypoglycemic agents (OHAs) and insulin (all p<0.001). Of these 1,795 respondents, 530 (29.5%) 
were severely obese (BMI ≥35) and the proportion of Class III obese (BMI ≥40) was greater than 
the proportion of those in the healthy weight range (BMI ≤25). Men were more highly 
represented in the overweight category but women comprised the majority in the BMI ≥ 35 and, 
in particular, BMI ≥ 40, categories.     
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After carefully matching the 530 participants with a BMI≥35 (cases) with 530 with a BMI <35 
(controls), there was no statistical difference between the groups on any of the matching 
variables, i.e. gender, age, duration of diabetes and use of insulin therapy (Table 2).  
Table 2 details the demographic, socioeconomic, clinical characteristics, and comorbidities of the 
controls and cases (including stratification by BMI).  Many indicators of socioeconomic 
disadvantage were more common in cases than controls, and for some there was increasing 
disadvantage with increasing BMI. Women predominated in the BMI >45 kg/m2 category where 
there were low levels of paid work and household income, and high levels of unemployment and 
dependence on disability pensions. The severely obese group was more likely to be single, living 
alone and less likely to have had formal education after leaving school.  
The severely obese group was not more likely than the control group to report specific serious 
micro- and macrovascular complications, but was more likely to report “vascular disease” 
generally. Respondents who responded positively to the presence of “vascular disease” in 
general were more likely to respond positively to any specific form of vascular disease (micro- 
or macrovascular), so providing internal consistency. With increasing levels of obesity, a 
predictable increase was observed in those reporting hypertension, obstructive sleep apnea and 
(for women only) polycystic ovary syndrome (PCOS). Sexual dysfunction was not influenced by 
BMI in either gender, but dysfunction was reported in 34% of men and 10% of women overall. 
Depression and Anxiety 
There was a clear increase in the median PHQ-9 score and the prevalence of moderate-severe 
depressive symptoms with increasing BMI (Table 3); 43% of participants with Class III obesity 
(BMI ≥ 40 kg/m2) reported moderate-severe depressive symptoms. Overall, 36% of the cases and 
controls combined reported a history of depression and of the total, 19% reported seeking help 
for depression. Increasing levels of obesity were associated with a greater discrepancy between 
numbers reporting a history of depression and those reporting a history of seeking help for 
depression (p=0.002; Table 3). 
Across the entire cohort (cases and controls combined), eight independent factors were 
associated with a higher PHQ-9 score: younger age (β=-0.16, p<0.001); receiving a disability 
pension (β=-0.14, p<0.001); no formal education qualification after leaving school (β=0.11, 
p<0.001); being unemployed (β=0.09, p=0.004); having a history of sexual dysfunction (β=0.12, 
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p<0.001), sleep apnea (β=0.13, p<0.001), PCOS (β=0.13, p<0.001), or vascular disease (β=0.14, 
p<0.001). β values represent standardized coefficients, with all variables included in the model 
explaining 21% of the variance. Gender and BMI were not predictors in this overall general 
linear regression model; however, the identified socioeconomic and comorbidity issues that were 
identified had already emerged as being significantly associated with increasing obesity. 
In the severely obese group, moderate-severe depressive symptoms were associated with four 
independent factors: receiving a disability pension; current unemployment; history of 
albuminuria and/or vascular disease. The details of the hierarchical build of the binary logistic 
regression model are shown in Table 4.  Eight independent factors were associated with 
moderate-severe depressive symptoms in the full cohort of 1,060 matched cases and controls 
(Table 5). Five of the eight factors were independent predictors of the total PHQ-9 score and 
moderate-severe depressive symptoms. Additional factors included BMI, a history of fatty liver 
disease, and using insulin therapy. Thus, BMI was associated with an increase in moderate-
severe depressive symptoms when modeled with and controlled for socioeconomic factors, and 
obesity- / diabetes-related comorbidity. Table 5 also shows the hierarchical binary logistic 
regression model identifying independent predictors of moderate-severe depressive symptoms 
stratified by gender. Important gender differences emerged, with sexual dysfunction 
independently associated with depressive symptoms in women but not men. Moderate-severe 
depressive symptoms were associated with unemployment and sleep apnea in men, and receipt of 
a disability pension and a history of albuminuria in women. When a PHQ-9 cutoff value of 12 
was examined, the same predictors emerged with one addition – that of a history of PCOS in 
women (OR 1.9 (1.0 3.5) p=0.047(27)). 
In contrast to the findings for depressive symptoms, there was no evidence of increasing levels of 
anxiety symptoms with increasing BMI. Similar factors were associated with increasing GAD-7 
scores as had been associated with increasing PHQ-9 scores. Nine independent factors were 
associated with a higher GAD-7 score when combining both cases and controls into a single 
cohort: younger age (β = -0.17, p<0.001); receiving a disability pension (β=0.11, p<0.001); no 
formal education qualification after school (β=0.11, p<0.001); unemployment (β=0.09, p=0.004); 
history of sexual dysfunction (β=0.12, p<0.001), sleep apnea (β=0.10, p=0.002), PCOS (β=-0.14, 
p<0.001), vascular disease (β=0.11, p=0.001), and retinopathy (β=0.11, p=0.006). These β values 
represent standardized coefficients with all variables included in the model explaining 17% of 
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variance. While the factors associated with GAD-7 total scores were essentially the same as for 
PHQ-9 scores, there was no association with increasing BMI. There was also no evidence at any 
stage during the linear regression model build that increasing BMI protected against anxiety 
symptoms (details not shown). 
A total of 160 participants in the two groups combined reported the combination of moderate-
severe symptoms of depression and anxiety, and in this group there was a weak but significant 
association with increasing BMI (r=0.08, p=0.009). 
 
Discussion 
The self-reported height and weight of Diabetes MILES – Australia respondents with type 2 
diabetes indicated an average BMI in the class I obese range, with 30% having a BMI in the 
severely obese range. These figures, while alarming, may underestimate the actual numbers of 
people in the severely obese range, as there is a tendency to self-report being taller and weighing 
less than one really does (28). In a very confronting way, the figures demonstrate the significant 
numbers of those with more severe forms of obesity among the type 2 diabetes population, as 
would be expected, given the overall growth in population waistlines and mean community BMI 
(4). Our results demonstrate that general emotional well-being is severely compromised, 
represented by the high prevalence of moderate-severe symptoms of depression, but not anxiety, 
in those who are severely obese, compared with a carefully matched control group. A similar 
pattern of increase in symptoms of depression, but not anxiety, was found in the Edinburgh 
Study in those with abdominal obesity, cardiovascular disease and type 2 diabetes (29). The 
association between obesity and major depressive disorder, but not anxiety, is also supported 
from cross-sectional general practice data from the Netherlands study of Depression and Anxiety 
(30). Perhaps somatic symptoms of sleepiness, poor energy and breathlessness may contribute to 
reducing anxiety symptoms and increasing those of depression. 
Severely obese respondents clearly had higher levels of demographic and socioeconomic 
disadvantage. Compared with controls, those who were severely obese were less likely to have a 
current partner, paid employment, health insurance, and university or higher educational 
qualifications. Living alone, lower income, unemployment, and receiving a disability pension 
were all more commonly reported. While these factors are inter-related, unemployment and 
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receiving a disability pension were most strongly associated with poor emotional well-being, 
demonstrated by increased symptoms of depression and/or anxiety. Obesity has previously been 
shown to be the single most important factor associated with poor productivity, work disability 
and impaired daily activities among US workers with diabetes (31). Finkelstein and colleagues 
have also demonstrated the health and productivity costs associated with increasing obesity, 
especially in those with a BMI >35 kg/m2 (18). The current study clearly demonstrates the 
presence of socio-demographic and economic disadvantage in the severely obese respondents 
and an association with symptoms of depression. The association between work and work-
related disability and depression in those with diabetes highlights the need to adequately assess 
and address both physical and psychological conditions (18). 
We confirm previously reported associations between symptoms of depression and obesity- and 
diabetes-related comorbidity in those with vascular disease, obstructive sleep apnea, 
microalbuminuria, fatty liver disease and sexual dysfunction (29; 32-34). Independent factors 
associated with depression identified groups at particular risk, for example younger men who are 
unemployed, using insulin and have sleep apnea; and women who are on a disability pension and 
report sexual dysfunction. While this clustering does not imply particular causal or counter-
causal relationships, it provides a practical clinical snapshot of those at risk and may allow for a 
more detailed and focused clinical discussion and evaluation. The interactions between type 2 
diabetes, severe obesity, depression, and cardiovascular risk and disease are established, and 
depressive illness is not an innocent bystander. In major depressive illness, stress pathways are 
activated, with increased sympathetic activity, reduced heart rate variability, increased cortisol 
levels, and elevated CRP levels (35; 36).  
Diabetes, obesity and depression are associated with great direct and indirect costs to the 
individual and the community (17; 37; 38). Better understanding of the combined issues 
experienced by severely obese Australians living with type 2 diabetes provides insights to inform 
the delivery of more effective chronic disease management plans. This includes the community 
and healthcare support needed to engage people with type 2 diabetes and obesity in optimal self-
care, which is critical to achieving better health outcomes, and more effective use of healthcare 
resources (39). A cycle of failure and frustration is experienced by those living with severe 
obesity (and their therapists alike), as a result of compounding socio-demographic, emotional, 
and physical health issues, together with the physiologically-driven inability to maintain often 
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unrealistic weight loss goals. The expected long-term weight loss from behavioral, lifestyle, 
dietary and pharmaco-therapeutic methods is very modest (3-5% of total body weight) and, while 
helpful, these methods do not achieve the levels desired by the individual or their therapist (40; 
41). Bariatric surgical options are indicated for people with type 2 diabetes and severe obesity 
(42) and are associated with marked improvement in quality of life and symptoms of depression 
(43). Procedures, now performed largely by laparoscopy, are highly effective in achieving and 
sustaining substantial weight loss, providing excellent glycemic benefits, and being cost-neutral 
if not actually providing a beneficial return on the health investment, due to productivity gains 
and reduced ongoing medical costs (20; 44). Delivering surgical options within a medical 
paradigm of chronic disease/diabetes management is challenging and integrated care models are 
currently unusual, yet this is exactly what is required. In addition, the challenge of equity of 
access to surgical options must be considered in light of the demographic and socioeconomic 
characteristics of severely obese individuals with type 2 diabetes identified in the current study.    
There are several important limitations to this study, many of which have been outlined 
elsewhere (23). It is a cross-sectional self-report survey including only those who volunteered to 
take part. Therefore, results cannot be used to estimate population prevalence of factors involved, 
including the presence of obesity, depression, anxiety and comorbidity. Additionally, the 
instruments used to measure symptoms of anxiety and depression, while widely used and well-
validated, are not diagnostic of these conditions, so caution must be exercised in the 
interpretation of emotional and psychological impairment. This study does, however, provide a 
detailed snapshot of the combined issues of severe obesity, demographic and socioeconomic 
disadvantage, comorbidity, and emotional well-being, and indicates several avenues that warrant 
further investigation and targeted intervention. Furthermore, we were conservative in adopting a 
control group of respondents with a BMI up to 34, rather than including only those in the healthy 
BMI range. Thus, compared with those in the healthy BMI range, those with severe obesity are 
likely to be even more disadvantaged in many respects. 
In conclusion, this study demonstrates that severely obese people living with type 2 diabetes 
have cumulative stressors related to health, disability, demographic and socioeconomic factors, 
and impaired emotional well-being. These cumulative stressors deserve consideration and 
awareness of these issues may assist in developing realistic and appropriate healthcare goals.  
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